Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Volker Kunzmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3615-7566; OpenAlex author ID A5070309355. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
107
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 5 papers · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers

Papers 26

  1. Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2026.117040↗
  2. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Last author DOI 10.1016/j.esmogo.2025.100274↗
  3. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  4. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116… Co-author DOI 10.1007/s00432-024-05827-x↗
  5. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Last author DOI 10.1016/j.esmoop.2024.103463↗
  6. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Last author DOI 10.1016/j.esmoop.2024.103705↗
  7. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  8. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  9. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  10. Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results… Co-author DOI 10.1016/j.ejrad.2023.110834↗
  11. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  12. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  13. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  14. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Last author DOI 10.1016/j.esmoop.2022.100552↗
  15. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
  16. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  17. Prognostic impact of simultaneous venous resections during surgery for resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.12.017↗
  18. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  19. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Co-author DOI 10.1097/mpa.0000000000000742↗
  20. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. First author DOI 10.2147/ott.s124097↗
  21. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitab… Co-author DOI 10.1093/annonc/mdw006↗
  22. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Co-author DOI 10.21037/jgo.2016.01.03↗
  23. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Co-author DOI 10.1093/jnci/dju413↗
  24. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000441310↗
  25. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Can… Co-author DOI 10.1159/000367966↗
  26. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. Last author DOI 10.1159/000348527↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Heinemann · 12 shared papers, 2015–2026 · strength 1.73
  2. Stefan Hubert Boeck · 10 shared papers, 2018–2026 · strength 1.52
  3. Thomas Jens Ettrich · 10 shared papers, 2018–2026 · strength 1.35
  4. Jens Thomas Siveke · 10 shared papers, 2015–2026 · strength 1.32
  5. Frank Kullmann · 9 shared papers, 2015–2026 · strength 1.17
  6. Brigitte Kimmel · 6 shared papers, 2022–2026 · strength 1.13
  7. Ingo Hartlapp · 8 shared papers, 2013–2026 · strength 1.02
  8. Friedrich Anger · 6 shared papers, 2020–2026 · strength 0.95
  9. Hana Algül · 6 shared papers, 2021–2026 · strength 0.88
  10. Uwe M. Martens · 5 shared papers, 2021–2026 · strength 0.76
  11. Steffen Ormanns · 3 shared papers, 2022–2026 · strength 0.63
  12. Dirk Waldschmidt · 4 shared papers, 2021–2024 · strength 0.53
  13. Uwe Pelzer · 4 shared papers, 2021–2024 · strength 0.53
  14. Anke Reinacher‐Schick · 4 shared papers, 2018–2024 · strength 0.49
  15. Oliver Waidmann · 3 shared papers, 2022–2024 · strength 0.44
  16. Danmei Zhang · 2 shared papers, 2023–2026 · strength 0.43
  17. Helmut Oettle · 3 shared papers, 2015–2024 · strength 0.38
  18. Dominik Paul Modest · 2 shared papers, 2024 · strength 0.33
  19. Christoph Benedikt Westphalen · 3 shared papers, 2018–2023 · strength 0.31
  20. Ingo Klein · 3 shared papers, 2020–2023 · strength 0.31
  21. Michael Haas · 3 shared papers, 2018–2023 · strength 0.31
  22. Klara Dorman · 2 shared papers, 2023–2024 · strength 0.30
  23. Sai Agash Surendran · 1 shared paper, 2026 · strength 0.29
  24. Michael Guenther · 1 shared paper, 2026 · strength 0.29
  25. Michael Geißler · 2 shared papers, 2023–2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.